Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Platelet-derived growth factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Platelet-derived growth factor receptor antagonists: Overview
Platelet-derived growth factor receptors belong to class III receptor tyrosine kinases. In human, there are four genes expressing PDGF chains: PDGF-A, B, C and D. PDGFA, PDGFB, PDGFC, and PDGFD genes are located on chromosomes 7, 22, 4, and 11, respectively. Platelet-derived growth factor plays a significant role in cell proliferation and embryonic development and is regulated through the platelet-derived growth factor receptor (PDGFR). Platelet-derived growth factor receptor (PDGFR) is a compelling target for developing therapeutic agents to treat diseases associated with overactivated platelet-derived growth factor (PDGF) signaling and has proved to be particularly encouraging for cancer treatment.
Report Highlights
This segment of the Platelet-derived growth factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Platelet-derived growth factor receptor antagonists Emerging Drugs
Further product details are provided in the report……..
Platelet-derived growth factor receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Platelet-derived growth factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
Platelet-derived growth factor receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Platelet-derived growth factor receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Platelet-derived growth factor receptor antagonists drugs.
Platelet-derived growth factor receptor antagonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Platelet-derived growth factor receptor antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Platelet-derived growth factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Platelet-derived growth factor receptor antagonists: Overview
Platelet-derived growth factor receptors belong to class III receptor tyrosine kinases. In human, there are four genes expressing PDGF chains: PDGF-A, B, C and D. PDGFA, PDGFB, PDGFC, and PDGFD genes are located on chromosomes 7, 22, 4, and 11, respectively. Platelet-derived growth factor plays a significant role in cell proliferation and embryonic development and is regulated through the platelet-derived growth factor receptor (PDGFR). Platelet-derived growth factor receptor (PDGFR) is a compelling target for developing therapeutic agents to treat diseases associated with overactivated platelet-derived growth factor (PDGF) signaling and has proved to be particularly encouraging for cancer treatment.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Platelet-derived growth factor receptor antagonists R&D. The therapies under development are focused on novel approaches for Platelet-derived growth factor receptor antagonists.
This segment of the Platelet-derived growth factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Platelet-derived growth factor receptor antagonists Emerging Drugs
- Lenvatinib: Eisai
- Quizartinib: Daiichi Sankyo Company
Further product details are provided in the report……..
Platelet-derived growth factor receptor antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Platelet-derived growth factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Platelet-derived growth factor receptor antagonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Platelet-derived growth factor receptor antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Platelet-derived growth factor receptor antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Platelet-derived growth factor receptor antagonists drugs.
Platelet-derived growth factor receptor antagonists Report Insights
- Platelet-derived growth factor receptor antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Platelet-derived growth factor receptor antagonists drugs?
- How many Platelet-derived growth factor receptor antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Platelet-derived growth factor receptor antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Platelet-derived growth factor receptor antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Platelet-derived growth factor receptor antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eisai
- Daiichi Sankyo Company
- Jiangsu Hengrui Medicine
- Boehringer Ingelheim
- Betta Pharmaceuticals
- Tyrogenex
- Pfizer
- Metagone Biotech
- Bayer Healthcare
- AROG Pharmaceuticals
- Pfizer
- Molecular Partners
- Xspray Pharma
- Lenvatinib
- Quizartinib
- Famitinib
- Nintedanib
- Vorolanib
- Axitinib
- MGD 1509
- Regorafenib
- Crenolanib
- AGN-151200
- Sorafenib nanoparticle formulation
Introduction
Executive Summary
Platelet-derived growth factor receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Platelet-derived growth factor receptor antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Platelet-derived growth factor receptor antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Platelet-derived growth factor receptor antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Lenvatinib: Eisai
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Quizartinib: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AGN-151200: Molecular Partners AG
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Platelet-derived growth factor receptor antagonists Key Companies
Platelet-derived growth factor receptor antagonists Key Products
Platelet-derived growth factor receptor antagonists- Unmet Needs
Platelet-derived growth factor receptor antagonists- Market Drivers and Barriers
Platelet-derived growth factor receptor antagonists- Future Perspectives and Conclusion
Platelet-derived growth factor receptor antagonists Analyst Views
Platelet-derived growth factor receptor antagonists Key Companies
Appendix
Executive Summary
Platelet-derived growth factor receptor antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Platelet-derived growth factor receptor antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Platelet-derived growth factor receptor antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Platelet-derived growth factor receptor antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Lenvatinib: Eisai
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
Quizartinib: Daiichi Sankyo Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
AGN-151200: Molecular Partners AG
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Platelet-derived growth factor receptor antagonists Key Companies
Platelet-derived growth factor receptor antagonists Key Products
Platelet-derived growth factor receptor antagonists- Unmet Needs
Platelet-derived growth factor receptor antagonists- Market Drivers and Barriers
Platelet-derived growth factor receptor antagonists- Future Perspectives and Conclusion
Platelet-derived growth factor receptor antagonists Analyst Views
Platelet-derived growth factor receptor antagonists Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Platelet-derived growth factor receptor antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Platelet-derived growth factor receptor antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Platelet-derived growth factor receptor antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Platelet-derived growth factor receptor antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
